← Trials/Trial dossier/NCT07255209
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）
Lead sponsor
Asset
Mazdutide
Subcutaneous · GLP-1 / glucagon dual
Listed sites
1
Recruiting sites
1
Enrollment
180
estimated
Study population
Obesity / overweight
Key I/E criterion
•BMI 586-2018
Primary endpoint
•BMI, change
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Participants must meet all of the following inclusion criteria to be enrolled:
Key Inclusion Criteria：
1. Male or female participants aged ≥12 years and <18 years at the time of signing the informed consent/assent form.
2. BMI at screening meeting the obesity criteria defined by "WS/T 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome.
3. Weight change <5 kg after ≥12 weeks of diet and exercise alone before screening (per self/parental report).
Exclusion criteria
Key Exclusion Criteria：
1. Prior diagnosis of type 1 diabetes.
2. Pre-pubertal participants (Tanner Stage I).
3. History of (or planned) bariatric surgery (except liposuction/abdominoplasty or acupuncture for weight loss performed >1 year before screening).
Endpoints (4)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Weight & body composition
4 endpointsPercent Change from Baseline in BMI
Time frame:Week 32
BMI, change
percent change from baseline, improvement
Percentage of Participants with ≥5% BMI Reduction
Time frame:Week 32
≥5% weight-loss responders
threshold achievement, improvement
Percent Change from Baseline in BMI
Time frame:Week 52
BMI, change
percent change from baseline, improvement
Percentage of Participants with ≥5% BMI Reduction
Time frame:Week 52
≥5% weight-loss responders
threshold achievement, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.